ACE-011: Phase IIa started

Celgene began a 2-part, double-blind Phase IIa (REN-001) trial in 32 patients. The first part will compare a single 0.1 mg/kg subcutaneous dose of ACE-011 vs. placebo in 8 patients. The second part wi...